











LEO Pharma Global Pipeline Overview

2022 Q1

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
DERMATOLOGY							
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema.						
Anti IgE⁺B-cell LP0201	A monoclonal antibody under development for atopic dermatitis and allergic asthma.	 					
Anti IL-22R LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.						
H4R antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.						
IL-17A PPI LP0200	An IL-17 small-molecule modulator under development for psoriasis.						

*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority. Any future availability of these compounds may be restricted globally.



MAT-53713 | January 2022

